Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 11/20 | 0.70 |
| ▸ | SLC12A5 | Q9H2X9 | 4/20 | 0.34 |
| ▸ | USP19 | O94966 | 3/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1916941 | 1.00 | FFAR2 (0.70) | FFAR2SLC12A5USP19MMP2MMP9 | |
| SCHEMBL16498340 | 0.90 | FFAR2 (0.69) | FFAR2SLC12A5MMP2MMP9MMP12 | |
| SCHEMBL1915893 | 0.89 | FFAR2 (0.71) | FFAR2SLC12A5USP19MMP2MMP9 | |
| SCHEMBL1915897 | 0.89 | FFAR2 (0.71) | FFAR2SLC12A5USP19MMP2MMP9 | |
| SCHEMBL2399168 | 0.89 | FFAR2 (0.70) | FFAR2SLC12A5 | |
| SCHEMBL1916762 | 0.89 | FFAR2 (0.70) | FFAR2SLC12A5 | |
| SCHEMBL1916398 | 0.87 | FFAR2 (0.70) | FFAR2SLC12A5 | |
| SCHEMBL1916394 | 0.87 | FFAR2 (0.70) | FFAR2SLC12A5 | |
| SCHEMBL2051654 | 0.86 | FFAR2 (0.71) | FFAR2SLC12A5MMP2MMP9MMP12 | |
| SCHEMBL2399185 | 0.86 | FFAR2 (0.71) | FFAR2SLC12A5MMP2MMP9MMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2011-09-22 | — | — | US | claimed |
| EP-2364297-A1 | Compounds, pharmaceutical composition and methods for use in treating metabolic disorders | Euroscreen S.A. (BE) | 2011-09-14 | — | — | EP | claimed |
| WO-2010066682-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | EUROSCREEN S.A. (BE) | 2010-06-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN TREATING METABOLIC DISORDERS | CPT1A, LIPC, PC | FFAR2 295/4885SLC12A5 715/4885USP19 2831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.